Structure Therapeutics Inc. GPCR
Updated: 12 Aug 2026
No signal published yet
We already track Structure Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Structure Therapeutics Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Structure Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, Structure Therapeutics reported its second quarter 2026 financial results and announced that the first patients were dosed in its Phase 3 ACCOMPLISH program for aleniglipron. The company reported $1.34 billion in cash, cash equivalents, and short-term investments as of June 30, 2026, which is expected to fund operations through 2028. Additionally, the company appointed John Berrios as Chief Commercial Officer.
What Firelda Watch includes for Structure Therapeutics Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Structure Therapeutics Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Structure Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more